According to the American Diabetes Association in their article “What you Need to Know: Important Information about the Inflation Reduction Act and Diabetes”, in recent news, the Inflation Reduction Act has taken center stage, offering a ray of hope to millions of Americans living with diabetes. This groundbreaking legislation brings significant relief to those who rely on insulin and other prescription drugs, especially seniors under Medicare. Let’s delve into what this act means for people with diabetes and how it’s set to reshape the landscape of healthcare affordability.
Affordable Insulin for Seniors with Medicare
Starting in 2023, the Inflation Reduction Act caps the monthly cost of insulin at a mere $35 for seniors under Medicare, including those who use insulin pumps. While some seniors have already been enjoying this benefit through Medicare Part D plans, this legislation ensures that all seniors using insulin can access this cost limit. Moreover, seniors could pay even less than $35 per month for insulin by 2026, thanks to changes in prescription drug pricing within Medicare Part D.
To ensure immediate relief, seniors charged more than $35 per month for insulin in the initial months following the new copay cap enactment will receive reimbursements. This provision guarantees that seniors won’t have to bear the brunt of soaring insulin costs any longer.
Comprehensive Relief for Diabetes Patients
But the Inflation Reduction Act doesn’t stop at insulin. It also sets a cap of $2,000 per year on the cost of all prescription drugs for seniors enrolled in Medicare Part D. Considering that one in every three dollars spent on prescription drugs in the U.S. goes toward diabetes management, this out-of-pocket limit is a game-changer for those who depend on multiple medications to survive.
Moreover, this act empowers Medicare to negotiate directly with drug manufacturers, effectively reducing the prices of some of the most expensive prescription drugs. This negotiation will significantly ease the burden of those relying on medications that were previously out of reach due to their exorbitant costs.
Extending Support for Private Insurance Plans
The Inflation Reduction Act doesn’t only benefit those under Medicare; it also offers relief to individuals and families with private insurance plans through the Affordable Care Act. Premium subsidies, which were expanded during the COVID-19 pandemic and set to expire, are now extended through 2025. This extension ensures that people with diabetes and other healthcare needs continue to receive financial assistance, making quality healthcare more accessible.
For more information visit:
“What you Need to Know: Important Information about the Inflation Reduction Act and Diabetes” by American Diabetes Association, . https://diabetes.org/sites/default/files/2022-08/What-People-with-Diabetes-Need-to-Know-about-the-Inflation-Reduction-Act.pdf
To learn about Medicare: